Tripp Levy PLLC is investigating potential claims on behalf of investors who purchased ARIAD Pharmaceuticals, Inc. ("ARIAD" or the "Company") (ARIA) stock between December 12, 2011 and October 17, 2013, inclusive (the “Class Period”).
The investigation concerns whether ARIAD and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 in connection with statements regarding the safety and efficacy of the Company’s leukemia drug Iclusig (ponatinib).
On December 11, 2011, ARIAD announced preliminary clinical data from the PACE trial of Iclusig, which purportedly yielded “strong clinical evidence of anti-leukemic activity of ponatinib,” and the Company touted the “favorable safety and tolerability profile of ponatinib.” On October 9, 2013, ARIAD reported that 11.8% of Iclusig-treated patients experienced serious arterial thrombosis. As a result, the Company said it was halting all enrollments in Iclusig clinical trials and that the Food and Drug Administration (FDA) had also placed a partial hold on the trials due to the arterial thrombosis occurring in Iclusig-treated patients. Following this news, ARIAD's stock price declined by $11.31 per share, or 66%, to close at $5.83 per share on October 9, 2013.
On October 18, 2013, ARIAD announced that the Company is “discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig in patients with newly diagnosed chronic myeloid leukemia.” According to the Company, the “U.S. Food and Drug Administration mutually agreed that the trial should be terminated because arterial thrombotic events were observed in patients treated with Iclusig.” On this news, shares of ARIAD dropped over 40% to $2.62 in intraday trading on October 18, 2013.
For more information about this investigation, please contact us at 1-877-772-3975 or email at contact @ tripplevy
NEW YORK--(BUSINESS WIRE)--
Tripp Levy PLLC is investigating the Board of Directors of Amarin Corporation plc (“Amarin” or the “Company”) (AMRN) for possible violations of federal securities laws.
On October 11, 2013, Amarin shares fell more than 20% to close at $5.09 after the Food & Drug Administration released its briefing documents for the October 16, 2013 advisory committee review of Amarin’s application to expand the use of its drug Vascepa. The FDA briefing documents raised questions about the mineral oil placebo potentially negatively impacting the control group data and consequentially overstating Vascepa’s effectiveness.
If you own Amarin stock and wish to obtain additional information about the investigation and your legal rights, please contact us at 1-877-772-3975
I don't understand your post...he forwards a newspaper article about their being a lawsuit on behalf of shareholders...how is that spam? If shareholders want more information they can call if not they don't. Seems like an informative posting for shareholders on this board whereas yours wasn't
The tender offer was launched today and is set to expireon November 6, 2013. Shareholders have until that time to join up and try and get a higher price. Here is number of law firm. The more shareholders who do the better the chances 1-877-772-3975
they also sent me the merger agreement which shows how management put in a penalty fee of $32 million to prevent someone from making a higher offer...crazy
September 30, 2013
New York, New York
Tripp Levy PLLC, a leading national securities and shareholder rights law firm, announces that it is investigating the acquisition of The Active Network, Inc. on behalf of shareholders. CTIVE Network (ACTV), announced that it has entered into a definitive agreement to be acquired by Vista Equity Partners (“Vista”), in an all cash transaction valued at approximately $1.05 billion. Under the terms of the agreement Vista will commence a tender offer to acquire all of the outstanding shares of ACTIVE’s common stock for $14.50 per share in cash,
The investigation concerns whether the board of directors of ACTV breached their fiduciary duties by not engaging in a full and fair auction of the company so that shareholders receive the maximum value for their shares while not, at the same time, seeking personal benefits for their own self interests. Indeed, the offer of $14.50 is below where the stock was trading at approx. 13 months ago and is below recent comparable transaction multiples in the industry including EBITDA, Cash Flows and Book Value.
If you are a shareholder of ACTV and would like additional information regarding this matter and how it affects your rights as a shareholder at no cost or expense, please contact us toll free at 1-877-772-3975 or email at contact @ tripplevy. Tripp Levy PLLC is a national law firm with extensive experience in mergers and takeovers and has recovered millions for shareholders around the globe.
September 23, 2013
New York, New York
Tripp Levy PLLC, a leading national securities and shareholder rights law firm, announces that it is investigating the acquisition of Greenway Medical Technologies. Under the terms of the agreement, Vista Equity Partners, which owns Vitera Healthcare Solutions, will pay Greenway stockholders $20.35 in cash for each share of Greenway common stock they hold.
Certain of Greenway’s stockholders (Investor Group L.P., Investor Growth Capital Limited and Pamlico Capital II, L.P.), each of Greenway’s directors and certain executive officers of Greenway, have each agreed to tender their shares into the offer, and vote their shares in favor of the definitive merger agreement and the merger, subject to certain terms and conditions. These stockholders collectively own approximately 50.9% of Greenway’s outstanding shares.
The investigation concerns whether these directors and officers acted for their own self interests and not for the benefit of shareholders in selling the company at this price to Vista. Indeed, the company has no debt and has over 14 million of cash on hand. If you are a shareholder of Greenway and would like additional information regarding this matter and how it affects your rights as a shareholder, at no cost or expense, please contact us toll free at 1-877-772-3975 or email at contact @ tripplevy
have you contacted the law firm? seems like the more shareholders who do the better the chances
I agree. Something doesn't seem right when management with 8% of the shares is voting in favor of this low ball deal. They must be keeping their jobs and getting options and cashed out their options. It just doesn't seem like a full sale took place and now with penalty fees for a new bidder to make a higher offer it seems management just took care of themselves at shareholders expense
agree....great point about the cash...why should it go to them and not shareholders.
that is a great point about the cash. They are getting $750 million which reduces the purchase price to them by $10 which means they are really only paying $115 per share which is highway robbery!
i agree that the price is too low. And why are they putting in a $300 million penalty fee to prevent other bidders from coming forward? shouldn't they be doing everything they can to get a higher price? I believe the preferred shares are owned by management, so here they are getting options and preferred shares worth hundreds of millions, keeping their jobs, getting millions more in more amgen options and then prevent us from getting a higher offer....if it smells fishy then it is fishy.
also enough with the lawyer bashing...it doesn't cost anything to join so there is no downside only upside.
I just heard that management of ALCO may not accept the higher offer of $14.30 from Everbright over Argonne
that management may be working with Argonne in trying to buy the company for themselves and they may try and find the everbright offer is not superior since they would not get to keep the company for themselves and may lose their lucrative jobs. Suggest everyone contact the law firm to prevent this from happening. we need a fair and open bidding war...that's the only way we will get the true market value. Here is number of law firm for you to call and join (at no cost) - 1-877-772-3975